AC Immune SA (ACIU) stock analysis
Healthcare · Biotechnology
From the 20-F filed 2026-03-13
How it makes money
It earns upfront and milestone payments by licensing its proprietary drug candidates to large pharmaceutical companies who assume the risks of clinical development.
The company does not yet sell commercial products. Instead, it relies on strategic partnerships where it grants major pharmaceutical entities exclusive rights to develop and potentially commercialize its therapies in exchange for periodic payments linked to project progress.
What protects it: the moat
Its competitive edge relies on proprietary technology platforms and patent protection, though it risks losing market exclusivity if intellectual property terms prove insufficient.
The company utilizes two internal platforms, SupraAntigen and Morphomer, to discover candidates. It asserts that these platforms allow it to address complex pathologies, though it acknowledges the inherent risk that patents may expire before products can capture significant market value.
What growth costs
It consumes significant cash through intensive research and development spending, while future clinical trials will be increasingly funded by its collaboration partners.
Operating costs are primarily driven by R&D activities required to advance its pipeline. The company does not currently manufacture or commercialize products; its growth model shifts the financial burden of late-stage clinical trials to its partners once licensing agreements are signed.
What could damage it
A partner's decision to terminate a clinical program permanently impairs the company's revenue stream by removing future milestone payments and research funding.
Because the company lacks internal commercialization infrastructure, it is entirely dependent on the strategic interest of partners to fund its development. If a partner terminates a collaboration, the company loses the vital capital flows supporting its R&D and is forced to re-evaluate the development path of the reclaimed asset.
About AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.